Merck Announces Fourth-Quarter 2014 Dividend

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.44 per share of the company’s common stock for the fourth quarter of 2014. Payment will be made on October 7, 2014, to stockholders of record at the close of business on September 15, 2014. About Merck Today s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Buy Bystolic (Nebivolol) with no Rx Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. Calan (Verapamil) with free prescription We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. Buy Bystolic (Nebivolol) with free Rx For more information, visit .merck.com and connect with us on Twitter, Facebook and YouTube. Merck Forward-Looking Statement This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Cytomid with free Rx These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Buy Protein Blends online If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. http://doctoranswers.wordpress.com Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (.sec.gov).

Texans Enjoying More Options with Custom Tailored Medications Prepared by Pharmacists

AUSTIN, Texas--(BUSINESS WIRE)--As changes in the nation’s healthcare system continue to pressure medical providers to be less generous with time and resources, Texas independent pharmacists are offering patients more through the practice of compounding. According to the Alliance of Independent Pharmacists of Texas (Alliance) .aiptexas.org, Texans are enjoying greater options in the medicines and dosages than ever before as more pharmacists create solutions to meet a patient’s individual unique need. The process of compounding includes making medication easier to swallow for a child or elderly patient, providing medications and dosages adapted for a patient’s specific need, providing medications not commercially manufactured and providing medications in short supply. Sherry Floyd was one such patient. For years, the Westlake, Texas, resident suffered from debilitating migraines that were often caused by muscle tension in her shoulders. Buy Anafranil Sr (Clomipramine) without prescription Common prescription medications for migraines didn’t help much, but recently she has been using a customized pain cream compounded by her local compounding pharmacy that has given her the best relief in years. Antabuse (Disulfiram) with no prescription “The pain cream has given me definite relief from the shoulder pain that often triggers my migraines,” said Floyd. “While many patients benefit from mass-produced medications, others greatly benefit from compounding,” said Nathan Pope, Pharm.D, FACA, Clinical Assistant Professor at The University of Texas at Austin College of Pharmacy. About Antabuse (Disulfiram) with free prescription “One patient’s needs may be different from another’s and compounding lets pharmacists and doctors work together to formulate a dosage and medication mix that is tailored to a specific patient. Buy Coumadin with free Rx Compounding pharmacists also supply surgery centers and doctors’ offices with medications that are not available through drug manufacturers.” The compounding medication was an essential role of pharmacists dating back to the origins of the profession: for hundreds of years, an individual pharmacist mixed each medicine for their patients. Buy Passion Flower online In the early 1950s, with the advent of mass-produced medications by drug manufacturers, compounding became less common. http://doctoranswers.wordpress.com More recently, as patients, doctors and pharmacists look for ways to address specific individual needs, compounding has regained popularity. Compounders, as well as all pharmacists, are highly trained healthcare professionals. Students graduate as a Doctor of Pharmacy (Pharm.D) by completing coursework that typically includes two years of pre-pharmacy work and four years of pharmacy school. They learn the chemistry of the human body and how it reacts with different medications and the final year includes a series of rotations on-site in different pharmacy settings. Additionally, pharmacists must receive 30 hours of continuing education every two years to keep their Texas pharmacy license current. Many compounders are also independent pharmacists who provide vital healthcare services to Texans in their communities. Community members often first visit independent pharmacists for suggestions and medical advice on symptoms. For patients who have limited or no healthcare coverage, independent pharmacists may be the only healthcare professional they see regularly. Patients that believe they might benefit from compounded medication should talk to their pharmacist or doctor to discuss options available to them. For more information on compounding, visit .aiptexas.org. NOTE TO MEDIA: Compounding pharmacists are located in many communities throughout Texas and we are happy to assist you in identifying a local pharmacist to provide their perspective and insight into the benefits of compounding for patients.

ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its second quarter 2014 financial results on Wednesday, August 6, 2014, before the market opens. Following the announcement, at 8:30 a.m. About Eldepryl (Selegiline) with no Rx Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast can be accessed by visiting the investor relations section of the Company’s website at investor.ariad.com. Elocon (Mometasone) with no Rx The call can be accessed by dialing 888-771-4371 (domestic) or 847-585-4405 (international) five minutes prior to the start time and providing the pass code 37600188. Buy Effexor (Venlafaxine) with no Rx A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks. About ARIAD ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. About Dexameth with no Rx ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. Buy Stress Vitamins online ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. http://medicalhelper.wordpress.com For additional information, visit .ariad.com or follow ARIAD on Twitter (@ARIADPharm).

. http://doctoranswers.wordpress.com Buy Stress online Buy Deworm About Duricef (Cefadroxil) with no Rx Buy Eldepryl (Selegiline) without Rx Elavil (Amitriptyline) without prescription

Covidien Launches EverFlexв„ў Self-expanding Peripheral Stent with Entrustв„ў Delivery System in Australia and New Zealand

DUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc today announced the launch of its EverFlex™ Self-expanding Peripheral Stent with Entrust™ Delivery System in Australia and New Zealand. The latest version of the EverFlex stent features the new Entrust Delivery System, which enables physicians to consistently place stents with accuracy, while providing the ease of a one-handed device. “It is impressive to see the existing EverFlex stent now available on an easy to use, low profile, triaxial designed delivery system,” said Michael Denton, associate professor, Epworth Hospital, Richmond. “With a lower profile, the puncture site is smaller, possibly resulting in fewer access site complications and faster ambulatory rates.” The Entrust Delivery System deploys the EverFlex stent, which is used to re-open narrowed (stenotic) regions of the superficial femoral and proximal popliteal arteries that supply blood to the legs. Narrowing of these arteries is associated with a condition known as peripheral arterial disease (PAD), where plaque builds along lining of the arteries, blocking blood flow to the legs. Buy Ocuflox (Ofloxacin) with free Rx The 36-month results from the DURABILITY II study demonstrate that even in long, complex lesions, the EverFlex stent is able to sustain patency and durability.1 Furthermore, with the Entrust Delivery System, physicians can deploy all sizes, up to 150 millimeter lengths, of the Covidien EverFlex stent on a low 5 F profile with preserved radial force. “Our Entrust Delivery System allows for one-handed delivery of the EverFlex stent for treating patients with PAD,” said Mark A. Omnicef (Cefdinir) without Rx Turco, MD, chief medical officer, Vascular Therapies, Covidien. Neggram (Nalidixic Acid) with no prescription “The design of the system is based on extensive physician feedback and procedural observation, and should allow for better performance during stent deployment.” About Covidien Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Buy Cardinol with free Rx Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products. Buy Hawthorn online With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries. http://medicalhelper.wordpress.com Please visit .covidien.com to learn more about our business.

AAIPharma Services and Cambridge Major Laboratories Announce Stephan Kutzer as Chief Executive Officer

WILMINGTON, N.C.--(BUSINESS WIRE)--AAIPharma Services Corp. (“AAIPharma”), a leading global provider of pharmaceutical analytical testing, product development and manufacturing services, and Cambridge Major Laboratories, Inc (“CML”), a global leader in pharmaceutical API development and manufacturing, announce the appointment of Stephan Kutzer, Ph.D. as Chief Executive Officer (CEO), effective August 1, 2014. “Stephan brings valuable leadership experience with over 18 years’ in the pharmaceutical industry. His diverse background in operations, technical services, API development and manufacturing positions him well to take our company to the next level,” said Susan Nestegard, acting CEO. About Eriacta (Sildenafil Citrate) with no Rx “He will continue our focus on best in class safety, quality, and exceeding customer expectations to achieve our vision of being the Contract Manufacturing and Development Organization (CDMO) of first choice in the pharmaceutical sector.” Most recently, Dr. About Estrace (Estradiol) with free prescription Kutzer served as Chief Operating Officer of Lonza, Inc. Eldepryl (Selegiline) with no prescription (part of the Lonza Group, a Swiss chemicals and biotechnology company). Benace with free Rx Since 2003, he has also served as Chief Operating Officer and/or President of several divisions, including Lonza Pharma Biotech Division, Lonza Custom Manufacturing, Lonza Biopharmaceuticals and Lonza Performance Chemicals. Buy Elderberry online From 1999 to 2002, he served as Site Director and Vice President of Operations of Lonza’s Bayport, Texas facilities, and in 1999, he was Director of Process Improvement at Lonza Guangzhou Ltd. http://allegra-opinion.blogspot.com Guangzhou, PR China. At Lonza Visp, he was Production and Plant Manager (1998) and Assistant Production Manager (1996) of Nicotinates. Dr. Kutzer holds a Master’s Degree in Chemical and Process Engineering and a Ph.D. in Engineering Sciences (Chemical Engineering) from the Technical University of Munich, Germany. “AAIPharma and Cambridge Major Laboratories are highly regarded for their expertise in pharmaceutical development and manufacturing services for clients around the world. These companies offer the unique set of people, capabilities and continuum of services required to enhance and expedite pharmaceutical development globally,” said Dr. Kutzer. “I am excited to be part of this high growth company and talented team.” About AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. have joined to form a world-class supplier of comprehensive pharmaceutical development and manufacturing services. With nearly 800 employees operating out of seven sites in the US and Europe, combined capabilities include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (solid dose and parenteral), packaging, and stability services. The family of companies is in the portfolio of American Capital, Ltd. (NASDAQ: ACAS). For more information on the companies, visit .aaipharma.com and .c-mlabs.com/.

Baxter Names Chief Financial Officers for New Biopharmaceutical Spin-off and Baxter International Inc.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) announced that upon completion of the tax-free distribution of the company’s biopharmaceuticals business, Robert J. Hombach, currently chief financial officer for Baxter International Inc., will be appointed chief financial officer and will assume additional operational responsibilities for the independent biopharmaceuticals company. Hombach will report to Ludwig N. Hantson, PhD., who will serve as the new company’s CEO. James K. Saccaro will rejoin Baxter August 4, 2014, and will assume the role of chief financial officer of Baxter International Inc., reporting to Robert L. Parkinson, Jr., Baxter’s chairman and CEO, following completion of the transaction in 2015. Both businesses require disciplined financial management of our global operations, including an intense focus on driving performance and enhancing value for our shareholders, said Parkinson. I’ve had the honor of working directly with Bob and Jay for many years, and both are extraordinary executives who bring deep knowledge of the businesses, financial experience and leadership as we advance our work to create two separate, independent healthcare companies. Hombach joined Baxter in 1989 and has served in a number of finance positions with increasing responsibility in financial planning, manufacturing, operations and treasury. Prior to assuming his current role in 2010, he served as corporate vice president and treasurer. Hombach also served as vice president of finance, Europe, and vice president of corporate planning, where he led several enterprise-wide initiatives and served as a member of the Baxter strategy team. Hombach earned his master s degree in business administration from Northwestern University s Kellogg Graduate School of Management, and his bachelor s degree in finance, cum laude, from the University of Colorado. Saccaro joined Baxter in 2002 and held a number of positions of increasing responsibility in both finance and operations for the company’s Medical Products and BioScience businesses. He was elected corporate vice president and treasurer in 2011. Saccaro rejoins Baxter from Hill-Rom Corporation, where he served as senior vice president and chief financial officer. Prior to joining Baxter, Saccaro started his career with the Walt Disney Company in strategic planning, and earned his master’s degree in engineering economic systems and a bachelor’s degree in economics, both from Stanford University. The biopharmaceuticals business, with 2013 annual revenues of approximately $6 billion, consists of a diverse portfolio of recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders, and plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions. This business s strategy is aimed at improving diagnosis, treatment and standards of care across a wide range of bleeding disorders and chronic diseases, enhancing capacity to meet growing demand for biotherapeutics, leveraging expertise into new emerging therapeutics through acquisitions and collaborations, and developing a robust new product pipeline focused on new and effective treatments that address unmet medical needs. The medical products business, with 2013 annual sales of more than $9 billion, offers a broad portfolio of intravenous (IV) solutions and nutritional therapies, drug delivery systems and administration sets, premixed and other injectable drugs, as well as inhalation anesthetics and hospital-based biosurgery products. This business is also integrating the Gambro AB acquisition, which complements Baxter s existing renal therapies franchise and provides customers a comprehensive portfolio of products and services to treat end-stage renal disease across the full continuum of care. The medical products company will focus on strengthening its market leadership through geographic expansion and increased penetration, leveraging its extensive hospital presence and global footprint, developing comprehensive solutions to improve patient outcomes and safety, and enhancing profitability through a more streamlined and flexible cost structure. Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. This release includes forward-looking statements concerning the planned separation of Baxter s biopharmaceutical and medical products businesses and the expected leadership of the two resulting companies after the separation. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the ability to successfully separate the businesses on the terms or timeline currently contemplated, if at all, and achieve the intended results, and other risks identified in Baxter s most recent filing on Form 10-K and other Securities and Exchange Commission filings, all of which are available on Baxter s website. Baxter does not undertake to update its forward-looking statements.

Fidia Completes Establishment of its Operations and Seeks Further Growth Opportunities in North America

PARSIPPANY, N.J. & ABANO TERME, Italy--(BUSINESS WIRE)--Fidia Pharma USA Inc., a wholly-owned subsidiary of Fidia Farmaceutici SpA, an international integrated company and recognized leader in hyaluronic acid-based products, announced today the completion of the establishment of its operations in the United States. Effective July 2014, the company’s sales force, previously operating under the contract sales organization Interpace BioPharma, a subsidiary of PDI, Inc., successfully transitioned to Fidia Pharma USA Inc. “This represents a key milestone in establishing Fidia in the US market.” says Mr. Aldo Donati, President of Fidia Pharma USA Inc. Buy Crixivan (Indinavir) with free prescription “We have created a fully integrated strategic and operational team of over 90 employees dedicated to maximize our growing Hyalgan® franchise (Sodium hyaluronate), intra-articular injections approved for the treatment of osteoarthritis of the knee, and pursue new internal and external business development opportunities.” Fidia Pharma USA’s national sales force coverage strengthens Fidia’s presence in the US market and constitutes a strong platform for further expansion. Buy Cyclogyl (Cyclopentolate) without Rx “We are seeking continued growth opportunities in North America, where we expect to leverage our global R&D pipeline and portfolio with the launch of new products. About Coumadin (Warfarin) without prescription We are also intensifying our efforts to identify synergic licensing, co-promotion and M&A opportunities, as well as expand Fidia s presence into Canada,” states Mr. Giorgio Foresti, CEO of Fidia Farmaceutici SpA. About Fidia Pharma USA Inc. Fidia Pharma USA Inc., headquartered in Parsippany, NJ, is a wholly-owned subsidiary of the multinational pharmaceutical company Fidia Farmaceutici SpA. Avomine with no prescription Fidia Pharma USA is focused on establishing and expanding Fidia’s position in the US and Canada markets, while upholding the company’s mission to provide consumers with innovative products that offer quality, safety and performance. Buy Dandelion online Drawing on the strengths of the parent company, Fidia Pharma USA s product portfolio focuses primarily on therapeutic areas such as Joint Healthcare and Advanced Wound Care. http://allegra-opinion.blogspot.com For more information, please visit .fidiapharma.us About Fidia Farmaceutici SpA Fidia Farmaceutici SpA is a multinational integrated pharma company headquartered in Abano Terme, Italy and based on extensive research on hyaluronan (GAG family) and its proprietary derivatives, with specialized technology platforms, that enable the company to produce hyaluronic acids with different molecular weights and characteristics, according to the indications designed for the finished products. Fidia Farmaceutici SpA products are marketed in over 100 countries worldwide, through fully owned subsidiaries and a comprehensive network of alliances and distributors. The company operates in diverse therapeutic areas, providing a wide array of innovative treatment options - medicinal products, medical devices, nutritional supplements and biomaterials - for application in Joint Healthcare, Advanced Wound Care, Dermatology and Aesthetics. Fidia Farmaceutici SpA is part of P&R Holding, a chemical group operating in the manufacturing of Active Pharmaceutical Ingredients, Advanced Intermediates, and High Potency Drugs dedicated to diseases with high socio-economic relevance. For more information, please visit .fidiapharma.com.

Research and Markets Italy Acne Market Highlights - 2014

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/2scjdt/italy_acne_market) has announced the addition of the "Italy Acne Market Highlights - 2014" report to their offering. The latest research, Italy Acne Market Highlights - 2014 , provides Italy acne market analysis, competitive landscape, and acne drug sales forecast in Italy. The research includes Italy acne market size estimates for 2013, market share forecast for six years to 2019, acne drugs market share, acne drugs sales estimates, acne drugs sales forecast, and acne late stage pipeline products. This research helps executives track competitor drugs sales and market share in Italy acne market. It supports decision making in R&D to long term marketing strategies. The report can be used for evaluating business opportunities, formulating business development strategies, and product positioning in the Italy acne market. Highlights of the Research: Marketed Acne Drugs in Italy Italy Acne Market Analysis Acne Drugs Sales Analysis in Italy Competitive Landscape in Italy Acne market Acne Late Stage Pipeline Italy Acne Market Forecast Acne Drugs Sales Forecast in Italy Future Competitive Landscape Key Topics Covered: 1. Acne - Disease Definition 2. Albenza (Albendazole) with free prescription Marketed Acne Drugs in Italy 3. About Aldactone (Spironolactone) with no prescription Italy Acne Market Analysis 3a. Buy Aldactone (Spironolactone) with no Rx Italy Acne Market Size 3b. About Accolate Drugs Sales in Italy Acne Market 4. Buy Alfalfa Tea online Competitive Landscape in Italy Acne Market 4a. http://webmdmagazine.wordpress.com Drugs Market Share in Italy Acne Market 4b. Generics Market Share in Italy Acne Market 4c. Acne Phase 3 Clinical Trial Pipeline Molecules 4d. Acne Phase 2 Clinical Trial Pipeline Molecules 5. Italy Acne Market - Future Market Outlook 5a. Italy Acne Market Size Forecast 5b. Drug Sales Forecast in Italy Acne Market 5c. Drugs Market Share in Italy Acne Market For more information visit .researchandmarkets.com/research/2scjdt/italy_acne_market

Acadian Seaplants Expansion Good News Story of the Year

 The completion of Acadian Seaplants Limited’s enhanced production facility and its acquisition of Ireland’s largest seaweed company combined to become BioNova’s good news story of the year for 2013/14. The announcement was made this evening at a gathering to celebrate the life sciences industry’s successes over the past year.

“There were a number of important milestones reached in the past year including significant investment being raised, new products being launched, positive clinical trial results and recognition for the innovators and entrepreneurs in the region”

Acadian Seaplants, Buy Minocin (Minocycline) with free Rx the global leader in the processing of seaweed-based products has made headlines recently with the completion of its multi-million dollar expansion in Cornwallis and the purchase of Arramara Teoranta on the west coast of Ireland, cementing the company’s position as the largest company of its kind in the world.
"We're honoured to be receiving the Good News Story award," Jean-Paul Deveau, President of Acadian Seaplants said. "Everyone has been working hard these last few years and yes, we've taken risks, but with a global vision, excellent technologies, excellent products and a great team, those risks are paying off." About Mobic (Meloxicam) with no Rx Deveau added that being acknowledged by his peers at BioNova was most rewarding. "The life sciences industry is inherently risky and we're all working hard under challenging conditions to grow our businesses," he said. "I'm flattered that we've been recognized among so many good stories."
Back in 2009, when most companies were slowing down because of the looming recession, Acadian Seaplants announced it would be expanding its Cornwallis plant to improve quality, boost productivity and increase exports. Buy Duphaston (Dydrogesterone) without Rx The grand opening of the Deveau Centre, which has improved production capacity by as much as 80 percent, takes place next week.
A selection panel comprised of three business journalists chose the Acadian Seaplants story among several others from the past 12 months.
“I like the risk taking side of the Acadian Seaplants story,” said one of the panel members. Acuitel with free prescription “I like how adept they were at reacting to the economic challenges and changes in their markets.”
According to BioNova CEO Marli MacNeil, 2013-14 was marked by a number of compelling stories for the life sciences community.
“There were a number of important milestones reached in the past year including significant investment being raised, new products being launched, positive clinical trial results and recognition for the innovators and entrepreneurs in the region,” she said. Buy Vitamins MacNeil added that with so much good news, she was glad she didn’t have to choose the winning story.
The announcement was made at BioNova’s Good News and Blues networking reception. In addition to highlighting the achievements in the past year, the event featured three bands made up of members of the life sciences community: Dalhousie School of Biomedical Engineering’s No Longer Hip; WebMD Helper The Replayables, made up of ACOA employees; and the Innovators featuring staff members from Innovacorp.
About BioNova
BioNova is Nova Scotia’s life sciences organization, representing companies working in drug & vaccine development, medical technologies, natural health products & nutraceuticals, digital health and bioproducts, as well as research organizations, service providers and other supporters.
About Acadian Seaplants
Acadian Seaplants Limited is a fully-integrated, bio-tech manufacturer of premium agricultural products, cultivated sea-vegetables and functional ingredients derived from select species of aquatic plants. Founded in 1981, Acadian established the seaweed industry in Canada and today is the world leader in marine plant products for people, animals and plants with exports to over 80 countries.

Ricoh Europe: Technology is Healthcare's Biggest Driver of Change but Executives Fear Impact on R&D

European healthcare executives (51 per cent) predict that over the next three years technology platforms will have the biggest impact on their business models, however they are wary that in driving rapid change the biggest areas at risk are 1) technology itself and crucially 2) R&D. The majority (71 per cent) believe their organisations need to change faster over the next three years if they are to be ready for the future and 78 per cent are feeling the pressure to change. 515-Pill without Rx The findings come from a new study called The Challenge of Speed, conducted by the Economist Intelligence Unit and sponsored by Ricoh. Healthcare respondents were from hospitals, medical device manufacturers and pharmaceuticals.
Carsten Bruhn, Executive Vice President, Ricoh Europe says, “Healthcare leaders know there is a lot to do and they need to change faster – the European Commission's eHealth Action Plan also covers many areas for change, from patient rights in cross-border healthcare to funding advanced R&D to ensuring that electronic health record systems are compatible internationally. Zyrtec (Cetirizine) without prescription But what do they start to change first, ensuring their R&D is protected?”
The study reveals that healthcare executives are fragmented. When asked where adapting to change was most crucial, they rated improving core business processes (34 per cent), recruiting new staff (34 per cent), attracting and retaining customers (34 per cent), optimising their supply chain (34 per cent) and adopting new technologies (32 per cent) with equal importance.
However, when specifically considering where they expect to see the most change in the next three years, the most cited response from healthcare executives was ‘improving their core business processes’. About Fosamax (Alendronate) without prescription What’s more, almost half rate data analytics as the technology with the most potential to improve healthcare over the next three years, much higher than any other industry (42 per cent versus average 29 per cent for respondents from all sectors).
Bruhn says, “Improving healthcare’s core business processes is without doubt the key starting point. It is also certain that data analytics will play a key role in preventative healthcare measures and direct future R&D. Healthcare leaders also need to focus on the digital transformation of document-heavy patient record systems. About Floxin (Ofloxacin) without prescription By doing so, they will have quicker access to information when they need it, while protecting confidentiality needs and dedicating more time to patient care.”
In the race to modernise more traditional ways of working and to realise the vision of the eHealth Action Plan, healthcare leaders also emphasise two significant barriers that are preventing them from making it happen more quickly. The first is the lack of a clear business case and the second is due to time constraints on healthcare professionals. In addition to the barriers to speed, the survey reveals additional bottlenecks to increasing overall agility. Buy Vitamins online The challenge of effectively linking technology platforms is ranked first and the presence of multiple and potentially conflicting initiatives is ranked in second place.
The healthcare industry is confronted with an overwhelming challenge when it comes to speeding up the progress of digital transformation. However, as this latest study shows, while technology platforms will have the biggest impact on business models, healthcare leaders are clear that’s not where the obstacles and bottlenecks lie.
Bruhn says, “The healthcare sector is not being held back due to a lack of investment in the right technology. Instead, as this study shows, it’s the processes behind the technology and the need for the right business case to optimise them. With the right support they can review existing processes and design an improvement plan. WebMD Help This will allow the IT systems already in place to be to integrated more effectively and time consuming administrative processes to be significantly reduced. Then with this renewed focus and the time saved, healthcare professionals will have more hours each day to focus on their R&D programmes and their absolute priority of delivering excellent healthcare services.”
For more insights into the challenge of speed facing healthcare organisations, visit www.allwebrx.com to download the full article and infographic and watch the video.

-ends-

| About Ricoh |
Ricoh is a global technology company specialising in office imaging equipment, production print solutions, document management systems and IT services. Headquartered in Tokyo, Ricoh Group operates in about 200 countries and regions. In the financial year ending March 2013, Ricoh Group had worldwide sales of 1,924 billion yen (approx. 20 billion USD).
The majority of the company's revenue comes from products, solutions and services that improve the interaction between people and information. Ricoh also produces award-winning digital cameras and specialised industrial products. It is known for the quality of its technology, the exceptional standard of its customer service and sustainability initiatives.
Under its corporate tagline, imagine. change., Ricoh helps companies transform the way they work and harness the collective imagination of their employees.
For further information, please visit www.fda-approved-rx.biz
| About the Research |
The report is based on a survey of 461 senior, Europe-based executives from a wide variety of industries. Their companies include a range of sizes. The survey sample is senior, with 49 per cent C-level or above and a further 23 per cent SVPs, VPs, or directors. In addition, the EIU conducted in-depth interviews with corporate leaders and noted experts as well as substantial desk research.